Pharsight

1. Axert patent expiration

Treatment: Treatment of migraine

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5565447 (Pediatric)	JANSSEN PHARMS	Indole derivatives	Nov, 2015 (10 years ago)
US5565447	JANSSEN PHARMS	Indole derivatives	May, 2015 (10 years ago)

Market Authorisation Date: 07 May, 2001

Dosage: TABLET

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
6.25 mg and 12.5 mg	08 Dec, 2005	1	07 Jul, 2015	07 May, 2015	Extinguished

Strength	Dosage	Availability
EQ 12.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued
EQ 6.25MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET	Discontinued

Treatment: Acute treatment of migraine attacks with or without aura in adults

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5464864	ENDO OPERATIONS	Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists	Nov, 2015 (10 years ago)
US5616603	ENDO OPERATIONS	Enantiomers of carbazole derivatives as 5-HT1 -like agonists	Apr, 2014 (11 years ago)
US5637611	ENDO OPERATIONS	Medicaments	Jun, 2014 (11 years ago)
US5827871	ENDO OPERATIONS	Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof	Oct, 2015 (10 years ago)
US5962501	ENDO OPERATIONS	Enantiomer of carbazole derivative as 5-HT1-like agonists	Dec, 2013 (12 years ago)

Market Authorisation Date: 08 November, 2001

Dosage: TABLET

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg	09 Mar, 2011	1	08 Jul, 2014	07 Nov, 2015	Eligible

Strength	Dosage	Availability
EQ 2.5MG BASE	TABLET	Prescription

Treatment: Treatment of migraine with or without aura

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5545644	UPJOHN	Indole derivatives	Dec, 2016 (9 years ago)
US6110940	UPJOHN	Salts of an anti-migraine indole derivative	Aug, 2017 (8 years ago)

Market Authorisation Date: 26 December, 2002

Dosage: TABLET

Strength	Dosage	Availability
EQ 20MG BASE	TABLET	Prescription
EQ 40MG BASE	TABLET	Prescription